Current treatment of dementia with Lewy bodies and dementia associated with Parkinson's disease
Identifieur interne : 001793 ( Main/Exploration ); précédent : 001792; suivant : 001794Current treatment of dementia with Lewy bodies and dementia associated with Parkinson's disease
Auteurs : David J. Burn [Royaume-Uni] ; Ian G. Mckeith [Royaume-Uni]Source :
- Movement Disorders [ 0885-3185 ] ; 2003-09.
English descriptors
- KwdEn :
Abstract
Dementia in Parkinson's disease (PDD) is a frequent and distressing complication with major consequences. Clinical and pathological features closely link PDD and dementia with Lewy bodies (DLB), suggesting they represent part of the same disease spectrum. Although dopaminergic deficiency primarily determines the akinetic–rigid symptoms of PDD and DLB, there is overwhelming evidence that cholinergic dysfunction underpins many of the cognitive impairments and psychotic features. Open‐label studies have suggested that cholinesterase inhibitor drugs may exert positive effects upon all aspects of the neuropsychiatric syndrome in PDD and DLB but particularly apathy, anxiety, impaired attention, hallucinations, delusions, sleep disturbance, and cognitive test performance. Worsening of extrapyramidal motor features is reported only rarely. Initial double‐blind, placebo‐controlled studies in PDD and DLB have so far confirmed these encouraging results. Early identification of PD patients at greatest risk of developing dementia would permit early use of disease modifying treatments which represent the “golden fleece” management approach to these groups. © 2002 Movement Disorder Society
Url:
DOI: 10.1002/mds.10566
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Current treatment of dementia with Lewy bodies and dementia associated with Parkinson's disease</title><author><name sortKey="Burn, David J" sort="Burn, David J" uniqKey="Burn D" first="David J." last="Burn">David J. Burn</name></author><author><name sortKey="Mckeith, Ian G" sort="Mckeith, Ian G" uniqKey="Mckeith I" first="Ian G." last="Mckeith">Ian G. Mckeith</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:12B2D89715074292A68071C2E22FE1B7287E4B51</idno><date when="2003" year="2003">2003</date><idno type="doi">10.1002/mds.10566</idno><idno type="url">https://api.istex.fr/document/12B2D89715074292A68071C2E22FE1B7287E4B51/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">002A42</idno><idno type="wicri:Area/Main/Curation">002685</idno><idno type="wicri:Area/Main/Exploration">001793</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Current treatment of dementia with Lewy bodies and dementia associated with Parkinson's disease</title><author><name sortKey="Burn, David J" sort="Burn, David J" uniqKey="Burn D" first="David J." last="Burn">David J. Burn</name><affiliation wicri:level="1"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Neurology, Regional Neurosciences Centre, Newcastle General Hospital</wicri:regionArea><wicri:noRegion>Newcastle General Hospital</wicri:noRegion></affiliation><affiliation wicri:level="1"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Institute for Ageing and Health, Wolfson Research Centre, Newcastle General Hospital</wicri:regionArea><wicri:noRegion>Newcastle General Hospital</wicri:noRegion></affiliation></author><author><name sortKey="Mckeith, Ian G" sort="Mckeith, Ian G" uniqKey="Mckeith I" first="Ian G." last="Mckeith">Ian G. Mckeith</name><affiliation wicri:level="1"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Institute for Ageing and Health, Wolfson Research Centre, Newcastle General Hospital</wicri:regionArea><wicri:noRegion>Newcastle General Hospital</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2003-09">2003-09</date><biblScope unit="volume">18</biblScope><biblScope unit="issue">S6</biblScope><biblScope unit="supplement">6</biblScope><biblScope unit="page" from="72">72</biblScope><biblScope unit="page" to="79">79</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">12B2D89715074292A68071C2E22FE1B7287E4B51</idno><idno type="DOI">10.1002/mds.10566</idno><idno type="ArticleID">MDS10566</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson's disease</term><term>cholinesterase inhibitor</term><term>dementia</term><term>dementia with Lewy bodies</term><term>treatment</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Dementia in Parkinson's disease (PDD) is a frequent and distressing complication with major consequences. Clinical and pathological features closely link PDD and dementia with Lewy bodies (DLB), suggesting they represent part of the same disease spectrum. Although dopaminergic deficiency primarily determines the akinetic–rigid symptoms of PDD and DLB, there is overwhelming evidence that cholinergic dysfunction underpins many of the cognitive impairments and psychotic features. Open‐label studies have suggested that cholinesterase inhibitor drugs may exert positive effects upon all aspects of the neuropsychiatric syndrome in PDD and DLB but particularly apathy, anxiety, impaired attention, hallucinations, delusions, sleep disturbance, and cognitive test performance. Worsening of extrapyramidal motor features is reported only rarely. Initial double‐blind, placebo‐controlled studies in PDD and DLB have so far confirmed these encouraging results. Early identification of PD patients at greatest risk of developing dementia would permit early use of disease modifying treatments which represent the “golden fleece” management approach to these groups. © 2002 Movement Disorder Society</div></front></TEI><affiliations><list><country><li>Royaume-Uni</li></country></list><tree><country name="Royaume-Uni"><noRegion><name sortKey="Burn, David J" sort="Burn, David J" uniqKey="Burn D" first="David J." last="Burn">David J. Burn</name></noRegion><name sortKey="Burn, David J" sort="Burn, David J" uniqKey="Burn D" first="David J." last="Burn">David J. Burn</name><name sortKey="Mckeith, Ian G" sort="Mckeith, Ian G" uniqKey="Mckeith I" first="Ian G." last="Mckeith">Ian G. Mckeith</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001793 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001793 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:12B2D89715074292A68071C2E22FE1B7287E4B51
|texte= Current treatment of dementia with Lewy bodies and dementia associated with Parkinson's disease
}}
| This area was generated with Dilib version V0.6.23. |  |